MMFSystemic sclerosis (SSc)SSc-ILDinterstitial lung disease (ILD)
…n their ILD by 24 months. Sixty-nine (93.2%) were on IS (mainly MMF) at time of HRCTs. Twenty-eight patients (37.8%) presented at l…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 541–600 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
N-Acetyl Cysteine7PPIs7Streptozotocin7fondaparinux7high-dose corticosteroids7hydroxyurea7naltrexone7tyrosine kinase inhibitors7vaccines7SGLT-2i6Glipizide6BLV6Varenicline6Camrelizumab6Cancer Drugs6Benzene6Doxy-PEP6SGLT-2is6Aprepitant6DEX6Dostarlimab6T-DXd6Azacitidine6Esketamine6NAC6Fidaxomicin6ITM6Minocycline6N-acetylcysteine6pMDIs6NBCA6Clofazimine6Filgotinib6Ravulizumab6Atomoxetine6Methylphenidate6amoxicillin-clavulanate6Acetylcysteine6Triamcinolone6anti-PD16Nitrous oxide6Octreotide6injectate6IL-1β6Lenalidomide6OAC6Venetoclax6antihypertensive drugs6n-BCA6Anti-TNF6Golimumab6Placebo6aripiprazole6b/tsDMARDs6Lansoprazole6MDPV6Mitomycin C6Nalbuphine6PCSK9 inhibitors6Sodium-Glucose Co-Transporter 2 Inhibitors6
Articles mentioning drugs
10,506 articles · page 661 of 876cyclophosphamideinterstitial lung disease (ILD)SSc-ILDinterstitial lung diseaseSystemic sclerosis (SSc)
… found a negative correlation level of IL-13 with total dose of cyclophosphamide (R=-0.248 (p<0.05)).Conclusions Our dates indirectly confirm th…
prednisoneNumeric Rating Scaleidiopathic pulmonary fibrosiscorticosteroid therapyCTD-ILD
…nts on corticosteroid therapy at doses higher than 10 mg/day of prednisone(or equivalent),with active infections or malignancies,were excl…
belimumabSSc-ILDGSKGSKSystemic sclerosis (SSc)United States National Institutes of Health Clinical Trial RegistryAmerican College of Rheumatologyinterstitial lung disease (ILD)ACR
…D study ( NCT05878717) is evaluating the efficacy and safety of belimumab in patients with SSc-ILD; it will be important to assess the re…
carbon monoxideInterstitial lung disease (ILD)SSc-ILDsystemic sclerosis (SSc)ILDAm J Respir Crit Care Med
…=0.01), total lung capacity (p=0.01) and diffusing capacity for carbon monoxide (p=0.004), although these associations did not remain significa…
ACAJohns Hopkins UniversitySSc-PAHpulmonary arterial hypertensionSSccancerinterstitial lung disease
…ohort B included 39 patients, of whom 53.8% tested positive for ACA, 41% for anti-SCL 70 antibodies, and 5.1% for anti-RNA polymera…
fibrillarinsystemic sclerosis (SSc)SSc
… hypertension, and rare scleroderma-specific antibodies (Th/To, fibrillarin).Notably, the distribution of first non-RP manifestations diffe…
EAT-10SScGERDgastroesophageal reflux disease
…re, which was associated with swallowing at risk of aspiration. EAT-10 might be useful PRO for screening aspiration in SSc.…
corticosteroidsystemic sclerosisSScGERDR Foundation for Statistical Computing
…=0.56), C-reactive protein (p=0.67), serum albumin (p=0.72) and corticosteroid use (p=1).Conclusions Our findings confirm that dysphagia is hi…
proton pump inhibitorssystemic sclerosisMarche University HospitalScleroderma UnitSSc
…esophageal involvement (78% vs 34%, p=0.001), reflux and use of proton pump inhibitors (71% vs 40% and 85% vs 56%, p=0.016 and 0.015, respectively) an…
Anti-centromereSystemic SclerosisLimited SScsclerodermaDermatomyositisMixed Connective Tissue DiseaseDMMCTD
…s prevalent in 90% of patients. The most common ANA pattern was Anti-centromere present in 50% of patients, Speckled in 20% and Nucleolar in 20…
IloprostSystemic Sclerosisvasoactive therapysystemic sclerosis (SSc)Calcinosis cutisscleroderma renal crisispulmonary arterial hypertensionSScDU
…hat the presence of CC was associated with an increasing use of Iloprost (H 3.73, 95% CI: 1.35-10.36, p=0.011), but not of ERA, PDE5i or…